← back to search

Paolo Tarantino

Harvard University · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, and Monoclonal and Polyclonal Antibodies Research.
h-index
35
citations
5,742
works
238
NIH funding
primary concept
Medicine
email

Recent publications

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Journal of Clinical Oncology 2024cited by 36position: firstdoi
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
Nature Communications 2024cited by 24position: middledoi
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment
Seminars in Oncology 2024cited by 20position: middledoi
Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future
ESMO Gastrointestinal Oncology 2024cited by 13position: middledoi
Detection of antibody–drug conjugate-induced interstitial lung disease using circulating cell-free DNA
ESMO Open 2024cited by 7position: middledoi
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
The Lancet Oncology 2023cited by 161position: middledoi
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
Nature Communications 2023cited by 59position: firstdoi
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
European Journal of Cancer 2023cited by 12position: middledoi
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
npj Breast Cancer 2022cited by 146position: firstdoi
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
npj Breast Cancer 2022cited by 15position: middledoi
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
CA A Cancer Journal for Clinicians 2021cited by 364position: firstdoi
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
JAMA Oncology 2021cited by 149position: firstdoi
Percutaneous Electrochemotherapy of Malignant Main Portal Veins Thrombosis: A Prospective Case Series
Journal of Hepatology 2016cited by 0position: middledoi
Percutaneous electrochemotherapy of malignant main portal veins thrombosis: a prospective case series.
Journal of Clinical Oncology 2016cited by 0position: middledoi
Percutaneous electrochemotherapy of malignant main portal veins thrombosis: A prospective case series
Digestive and Liver Disease 2016cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Giuseppe Curigliano · Istituti di Ricovero e Cura a Carattere Scientifico4 papers (2021–2023)Sara M. Tolaney · Medidata (United States)4 papers (2021–2024)Paolo Gallo · University of Padua3 papers (2016–2016) · 3 papers (2016–2016)Javier Cortés · Universidade Nova de Lisboa3 papers (2021–2022) · 2 papers (2016–2016)Fabrice André · Institut Gustave Roussy2 papers (2021–2022) · 2 papers (2016–2016)Chiara Corti · Harvard University2 papers (2021–2022)Albert Grinshpun · Yale Cancer Center2 papers (2024–2024) · 2 papers (2016–2016) · 2 papers (2016–2016)Shanu Modi · Beneficência Portuguesa de São Paulo2 papers (2021–2021) · 2 papers (2016–2016) · 2 papers (2016–2016) · 2 papers (2016–2016)Aviad Zick · Hadassah Medical Center2 papers (2024–2024)Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2022–2022) · 1 papers (2023–2023)Aryeh Babkoff · Hebrew University of Jerusalem1 papers (2024–2024)